4DMedical CT:VQ TGA Approval Australia

4DMedical Limited Limited announced that its CT:VQ technology has received Australia — Therapeutic Goods Administration (TGA) approval, allowing its commercial deployment across Australia. This non-contrast, CT-based ventilation-perfusion imaging solution provides functional lung information without the need for injected contrast agents or radiotracers, leveraging existing CT infrastructure. The approval is a significant milestone for 4DMedical Limited, expanding access to advanced respiratory diagnostics in Australia, a market with high CT scanner density. CT:VQ has already received regulatory clearance in other regions including the United States, European Union, United Kingdom, Canada, and New Zealand, and has been deployed at several leading U.S. institutions.